Eli Lilly and Company (NYSE:LLY) was the target of some unusual options trading on Friday. Stock traders purchased 244 put options on the company. This is an increase of approximately 132% compared to the average volume of 105 put options.
A number of brokerages recently weighed in on LLY. UBS AG lowered Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a report on Wednesday. Piper Jaffray Companies reaffirmed a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a report on Monday, April 17th. Argus lowered Eli Lilly and from a “buy” rating to a “hold” rating and upped their price objective for the stock from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reaffirmed a “buy” rating and set a $93.00 price objective on shares of Eli Lilly and in a report on Thursday, June 22nd. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $88.00 price objective on shares of Eli Lilly and in a report on Sunday, May 21st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $88.37.
Shares of Eli Lilly and (LLY) traded up 0.10% during mid-day trading on Friday, hitting $83.10. The stock had a trading volume of 3,820,069 shares. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72. The company has a 50 day moving average price of $82.91 and a 200 day moving average price of $81.37. The firm has a market cap of $87.85 billion, a P/E ratio of 35.96 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.50% and a net margin of 11.12%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 EPS. Equities analysts forecast that Eli Lilly and will post $4.15 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.
In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now owns 124,265,804 shares of the company’s stock, valued at $10,491,761,831.72. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last three months, insiders sold 474,733 shares of company stock worth $39,634,487. Corporate insiders own 0.20% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Joel Isaacson & Co. LLC boosted its position in shares of Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares in the last quarter. Franklin Street Advisors Inc. NC acquired a new position in shares of Eli Lilly and during the first quarter worth $320,000. Washington Trust Bank increased its position in shares of Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares in the last quarter. Finally, Independent Advisor Alliance acquired a new position in shares of Eli Lilly and during the fourth quarter worth $1,547,000. Institutional investors and hedge funds own 75.56% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/07/30/investors-purchase-high-volume-of-put-options-on-eli-lilly-and-company-nyselly-updated-updated-updated.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.